[MP-202534] Taletrectinib (NSCLC)
Last updated 30.04.2026
Project no.:
MP-202534
Report type:
Joint Clinical Assessment, JCA
Status:
Commission work started
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
Treatment of ROS1 positive advanced non-small cell lung cancer
Note:
This Joint Clinical Assessment (JCA) is being conducted in cooperation with the Dental and Pharmaceutical Benefits Agency (TLV) Sweden.
Further background information can be found here: European health technology assessment
| Stage | Date |
|---|---|
| Start | 1st quarter, 2026 |
| voraussichtlicher Abschluss | 1st quarter, 2027 |